Calcium and Tenofovir Disoproxil: what the published research says
PubMed indexes 8 records that name Calcium and Tenofovir Disoproxil together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Calcium and Tenofovir Disoproxil. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
A study appearing here is not proof that an interaction exists. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
NutriStack’s own interaction assessment for this pair is not published here. It has not completed qualified-human clinical review, so it is withheld from search. See the publication gate.
Nothing here is medical advice. Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen.
The research
8 studies naming Calcium and Tenofovir Disoproxil.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
“Vitamin D2 and calcium supplements should be considered for HIV-infected patients receiving TDF/FTC/EFV in a resource-limited setting where there are limited ART options (Clinicaltrials. gov NCT0287643).”
Names both Calcium and Tenofovir Disoproxil in its title.
Journal of the Formosan Medical Association = Taiwan yi zhi · 2026 · PMID 42025507
“In TDF-treated CHB patients, 48-week vitamin D2 and calcium supplementation did not meet the primary endpoint of PTH change. However, it was associated with a trend toward preserving BMD, particularly in those with baseline vitamin D deficiency.”
Names both Calcium and Tenofovir Disoproxil in its title.
Advances in pharmacological sciences · 2018 · PMID 30687401
“Optimal concentrations for 25-hydroxy vitamin D and calcium might therefore be different in people using TDF than expected from general populations but also people living with HIV with non-TDF-containing antiretroviral therapy. This might require different supplementation strategies but warrants further investigation.”
Names both Calcium and Tenofovir Disoproxil in its title.
“Although participants randomized to TDF-ART had larger decreases in CrCl from entry compared with participants randomized to iNVP, differences attenuated overtime and were not clinically significant. TDF-containing ART had no observed safety concerns for maternal renal function during the postpartum period.”
Names Calcium and Tenofovir Disoproxil together in an interaction, co-administration, or pharmacokinetic context.
“Although mean maternal calculated CrCl at Delivery was lower in the TDF-ART arm, the difference between arms is unlikely to be clinically significant. During pregnancy, the TDF-ART regimen had no observed safety concerns for maternal or infant renal function.”
Names Calcium and Tenofovir Disoproxil together in an interaction, co-administration, or pharmacokinetic context.
Limitations
What this evidence cannot tell you.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.
Nearby evidence
Other pairs with published research.
Pages covering Calcium or Tenofovir Disoproxil alongside a different substance.
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Calcium, Tenofovir Disoproxil, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
